TGF-β1/Smad通路通过参仙升脉口服液改善增龄性大鼠窦房结纤维化的表达变化
|
摘要
目的:观察TGF-β1/Smad通路在参仙升脉口服液改善增龄性大鼠窦房结纤维化中的表达变化。方法:SD大鼠60只,其中3月龄20只、12月龄大鼠20只、18月龄大鼠20只,随机分为两组即实验组和对照组。实验组大鼠每日灌胃参仙升脉口服液2 m L,30 d后取材。HE染色观察窦房结组织病理变化;Western-blot检测TGF-β1、Smad 2、Smad3、Smad 7蛋白的表达水平。结果:对照组中,12月龄组和18月龄组大鼠窦房结组织纤维化程度较重,3月龄组无纤维化改变不明显;TGF-β1、Smad 2、Smad 3表达水平随月龄增长升高,Smad 7表达水平降低。实验组与对照组相比,12月龄组与18月龄组大鼠窦房结组织病理程度明显降低,TGF-β1、Smad 2、Smad 3表达水平明显降低,Smad 7表达水平提高,而3月龄组大鼠实验组与对照组无明显差异。结论:参仙升脉口服液能降低增龄性大鼠TGF-β1、Smad 2、Smad 3表达水平,提高Smad 7表达水平,延缓窦房结纤维化进程。
Objective: To observe the expression of TGF-β1/Smad pathway in the treatment of senile rat sinoatrial node fibrosis with Shenxian Shengmai Oral Liquid. Methods: Sixty SD rats were randomly divided into two groups: experimental group and control group( n = 20),20 rats aged 12 months and 20 rats in 18 months old. The rats in the experimental group were given 2 m L of Shenxian Shengmai Oral Liquid daily for 30 days. The expressions of TGF-β1,Smad 2,Smad 3 and Smad 7 were detected by Western blotting. The expressions of TGF-β1,Smad 2,Smad 3 and Smad 7 were detected by HE staining. Results: In the control group,the degree of fibrosis of the sinoatrial node was heavier in the 12-month and 18-month-old rats,and the fibrosis was not changed in the 3-month group. The expressions of TGF-β1,Smad 2 and Smad 3 were increased and the expression of Smad7 was decreased with the aging. Compared with the control group,the histopathological changes of the sinoatrial node were significantly decreased in the 12-month and 18-month-old rats,the expressions of TGF-β1,Smad 2 and Smad 3 were significantly decreased and the expression of Smad 7 was increased. There was no significant difference between the experimental group and the control group in the age group. Conclusion: Shenxian Shengmai Oral Liquid can decrease the expressions of TGF-β1,Smad 2 and Smad 3,increase the expression of Smad 7 and delay the process of sinus node fibrosis.
Objective: To observe the expression of TGF-β1/Smad pathway in the treatment of senile rat sinoatrial node fibrosis with Shenxian Shengmai Oral Liquid. Methods: Sixty SD rats were randomly divided into two groups: experimental group and control group( n = 20),20 rats aged 12 months and 20 rats in 18 months old. The rats in the experimental group were given 2 m L of Shenxian Shengmai Oral Liquid daily for 30 days. The expressions of TGF-β1,Smad 2,Smad 3 and Smad 7 were detected by Western blotting. The expressions of TGF-β1,Smad 2,Smad 3 and Smad 7 were detected by HE staining. Results: In the control group,the degree of fibrosis of the sinoatrial node was heavier in the 12-month and 18-month-old rats,and the fibrosis was not changed in the 3-month group. The expressions of TGF-β1,Smad 2 and Smad 3 were increased and the expression of Smad7 was decreased with the aging. Compared with the control group,the histopathological changes of the sinoatrial node were significantly decreased in the 12-month and 18-month-old rats,the expressions of TGF-β1,Smad 2 and Smad 3 were significantly decreased and the expression of Smad 7 was increased. There was no significant difference between the experimental group and the control group in the age group. Conclusion: Shenxian Shengmai Oral Liquid can decrease the expressions of TGF-β1,Smad 2 and Smad 3,increase the expression of Smad 7 and delay the process of sinus node fibrosis.
引文
[1]Dobrzynski H,Boyett MR,Anderson RH.New insights into pacemaker activity:promoting understanding of sick sinus syndrome[J].Circulation,2007:1921-1932.
[2]Adán V,Crown LA.Diagnosis and treatment of sick sinus syndrome[J].Am Fam Physician,2003,67(8):1725-1732.
[3]张晓华,于德洵,钱锋.病态窦房结综合征中西医研究进展[J].中国临床研究,2014,6(15):10-12.
[4]Verrecchia F,Mauviel A.Transforming growth factor-beta and fibrosis[J].World J Gastroenterol,2007,13:3056-3062.
[5]彭瑞云,刘燕青,高亚兵,等.一种成年大鼠窦房结精定位和取材的方法[J].中国:CN201210477715,2013-03-13.
[6]Takeshita K,Fujimori T,Kurotaki Y,et al.Sinoatrial nodedysfunctionand early unexpected death of mice with a defect of klotho gene expression[J].Circulation,2004,109(14):1776-1782.
[7]房晨鹂,蔡盈盈,邓珏琳.Klotho基因多态性与病态窦房结综合征的关系[J].现代预防医学,2013,40(20):372-375.
[8]Xiao N,Zhang Y,Zheng Q,et al.Klotho is a serum factor related to human aging[J].Chin Med J,2004,117(5):742-747.
[9]王贵华,汪汉,孙梅芹,等.衰老相关基因Klotho在小鼠心脏表达的增龄性变化[J].中国老年学杂志,2012,8(32):3214-3216.
[10]赵晓燕,苏金林,张兴凯.TGF-β/Smads信号通路在心血管重构中的作用研究进展[J].河北医药,2010,32(17):2415-2416.
[11]钟之洲.黄志强治疗缓慢型性心律失常探析[J].浙江中医药大学学报,2008,32(1):68-69.
[12]刘淑娟,尹克春,周文斌,等.温补肾阳法治疗缓慢性心律失常的疗效观察[J].广东医学,2009,30(7):1167-1168.
[13]白丽梅,刘国勋,周进国.益气助脉方治疗缓慢性心律失常的临床研究[J].辽宁中医杂志,2014,41(2):285-286.
[14]王振涛,韩丽华,朱明军,等.孙建芝教授辨治病态窦房结综合征经验[J].中华中医药杂志,2007,22(9):616-617.
[15]吴启相.缓慢性心律失常辨证论治浅识[J].实用中医内科志,2010,24(9):48-49.
[16]谭子富,方孝俊,黄金星,等.参仙升脉口服液与阿托品治疗缓慢性心律失常的疗效观察[J].中西医结合心脑血管病杂志,2012,10(2):162.
[17]徐红娟,郭燕.参仙升脉口服液治疗病态窦房结综合征35例[J].中医杂志,2013,54(12):1054-1056.
[18]胡建华,陈世健,华小丽.参仙升脉口服液治疗病态窦房结综合征窦性心动过缓的临床研究[J].中成药,2012,34(1):7-9.
[19]白静.参仙升脉口服液治疗缓慢性心律失常的临床观察[J].中国实用医药,2013,8(21):169-170.
[20]苗静,侯平.参仙升脉与人工心脏起搏器对缓慢性心律失常患者生活质量影响等效性随机平行对照研究[J].实用中医内科杂志,2014(1):16-18.
[21]魏瑾.参仙升脉口服液干预心阳虚证缓慢性心律失常大鼠的实验研究[D].沈阳:辽宁中医药大学,2016.
[22]刘越,刘宁,侯平,等.参仙升脉口服液调控心率作用机制的研究[J].临床心电学杂志,2017,26(1):23-26.
[2]Adán V,Crown LA.Diagnosis and treatment of sick sinus syndrome[J].Am Fam Physician,2003,67(8):1725-1732.
[3]张晓华,于德洵,钱锋.病态窦房结综合征中西医研究进展[J].中国临床研究,2014,6(15):10-12.
[4]Verrecchia F,Mauviel A.Transforming growth factor-beta and fibrosis[J].World J Gastroenterol,2007,13:3056-3062.
[5]彭瑞云,刘燕青,高亚兵,等.一种成年大鼠窦房结精定位和取材的方法[J].中国:CN201210477715,2013-03-13.
[6]Takeshita K,Fujimori T,Kurotaki Y,et al.Sinoatrial nodedysfunctionand early unexpected death of mice with a defect of klotho gene expression[J].Circulation,2004,109(14):1776-1782.
[7]房晨鹂,蔡盈盈,邓珏琳.Klotho基因多态性与病态窦房结综合征的关系[J].现代预防医学,2013,40(20):372-375.
[8]Xiao N,Zhang Y,Zheng Q,et al.Klotho is a serum factor related to human aging[J].Chin Med J,2004,117(5):742-747.
[9]王贵华,汪汉,孙梅芹,等.衰老相关基因Klotho在小鼠心脏表达的增龄性变化[J].中国老年学杂志,2012,8(32):3214-3216.
[10]赵晓燕,苏金林,张兴凯.TGF-β/Smads信号通路在心血管重构中的作用研究进展[J].河北医药,2010,32(17):2415-2416.
[11]钟之洲.黄志强治疗缓慢型性心律失常探析[J].浙江中医药大学学报,2008,32(1):68-69.
[12]刘淑娟,尹克春,周文斌,等.温补肾阳法治疗缓慢性心律失常的疗效观察[J].广东医学,2009,30(7):1167-1168.
[13]白丽梅,刘国勋,周进国.益气助脉方治疗缓慢性心律失常的临床研究[J].辽宁中医杂志,2014,41(2):285-286.
[14]王振涛,韩丽华,朱明军,等.孙建芝教授辨治病态窦房结综合征经验[J].中华中医药杂志,2007,22(9):616-617.
[15]吴启相.缓慢性心律失常辨证论治浅识[J].实用中医内科志,2010,24(9):48-49.
[16]谭子富,方孝俊,黄金星,等.参仙升脉口服液与阿托品治疗缓慢性心律失常的疗效观察[J].中西医结合心脑血管病杂志,2012,10(2):162.
[17]徐红娟,郭燕.参仙升脉口服液治疗病态窦房结综合征35例[J].中医杂志,2013,54(12):1054-1056.
[18]胡建华,陈世健,华小丽.参仙升脉口服液治疗病态窦房结综合征窦性心动过缓的临床研究[J].中成药,2012,34(1):7-9.
[19]白静.参仙升脉口服液治疗缓慢性心律失常的临床观察[J].中国实用医药,2013,8(21):169-170.
[20]苗静,侯平.参仙升脉与人工心脏起搏器对缓慢性心律失常患者生活质量影响等效性随机平行对照研究[J].实用中医内科杂志,2014(1):16-18.
[21]魏瑾.参仙升脉口服液干预心阳虚证缓慢性心律失常大鼠的实验研究[D].沈阳:辽宁中医药大学,2016.
[22]刘越,刘宁,侯平,等.参仙升脉口服液调控心率作用机制的研究[J].临床心电学杂志,2017,26(1):23-26.